Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease

Catherine Pan, Ané Korff, Douglas Galasko, Carmen Ginghina, Elaine Peskind, Ge Li, Joseph Quinn, Thomas J. Montine, Kevin Cain, Min Shi, Jing Zhang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Meso Scale Discovery (MSD) recently established electrochemiluminescence-based assays to measure cerebrospinal fluid (CSF) levels of total tau (t-tau) and amyloid-β 1-42 peptide (Aβ42) that can aid in the diagnosis of Alzheimer's disease (AD). The goal of this investigation is to independently evaluate this platform and establish cut-off values of these biomarkers for AD diagnosis. Objective: To validate the analytical and clinical performance of the MSD t-tau and Aβ42 kits and propose diagnostic cut-off values for the field. Methods: The analytical performance of the CSF t-tau and Aβ42 assays was determined, followed by assessment of diagnostic performance of CSF t-tau, Aβ42, and t-tau/Aβ42 in three clinically characterized cohorts. Results: Both MSD assays demonstrated consistent and stable analytical performance, as well as resistance to several important pre-analytic variables. Diagnostically, t-tau/Aβ42 performed the best. Conclusions: Our results independently confirm the analytical and clinical performance of the MSD CSF t-tau and Aβ42 assays. Based on a large, multi-center, clinically-diagnosed cohort, we propose for the first time candidate diagnostic cut-offs for MSD measured CSF t-tau, Aβ42, and t-tau/Aβ42. However, these values needs to be refined as more subjects are included and the assays are tested by other laboratories.

Original languageEnglish (US)
Pages (from-to)709-719
Number of pages11
JournalJournal of Alzheimer's Disease
Volume45
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Amyloid
Cerebrospinal Fluid
Alzheimer Disease
Peptides
tau-1 monoclonal antibody
Biomarkers

Keywords

  • Alzheimer's disease
  • cerebrospinal fluid
  • Meso Scale Discovery
  • tau

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease. / Pan, Catherine; Korff, Ané; Galasko, Douglas; Ginghina, Carmen; Peskind, Elaine; Li, Ge; Quinn, Joseph; Montine, Thomas J.; Cain, Kevin; Shi, Min; Zhang, Jing.

In: Journal of Alzheimer's Disease, Vol. 45, No. 3, 2015, p. 709-719.

Research output: Contribution to journalArticle

Pan, C, Korff, A, Galasko, D, Ginghina, C, Peskind, E, Li, G, Quinn, J, Montine, TJ, Cain, K, Shi, M & Zhang, J 2015, 'Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease', Journal of Alzheimer's Disease, vol. 45, no. 3, pp. 709-719. https://doi.org/10.3233/JAD-143099
Pan, Catherine ; Korff, Ané ; Galasko, Douglas ; Ginghina, Carmen ; Peskind, Elaine ; Li, Ge ; Quinn, Joseph ; Montine, Thomas J. ; Cain, Kevin ; Shi, Min ; Zhang, Jing. / Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease. In: Journal of Alzheimer's Disease. 2015 ; Vol. 45, No. 3. pp. 709-719.
@article{8963d0c796534cb29358007e733c90a9,
title = "Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease",
abstract = "Background: Meso Scale Discovery (MSD) recently established electrochemiluminescence-based assays to measure cerebrospinal fluid (CSF) levels of total tau (t-tau) and amyloid-β 1-42 peptide (Aβ42) that can aid in the diagnosis of Alzheimer's disease (AD). The goal of this investigation is to independently evaluate this platform and establish cut-off values of these biomarkers for AD diagnosis. Objective: To validate the analytical and clinical performance of the MSD t-tau and Aβ42 kits and propose diagnostic cut-off values for the field. Methods: The analytical performance of the CSF t-tau and Aβ42 assays was determined, followed by assessment of diagnostic performance of CSF t-tau, Aβ42, and t-tau/Aβ42 in three clinically characterized cohorts. Results: Both MSD assays demonstrated consistent and stable analytical performance, as well as resistance to several important pre-analytic variables. Diagnostically, t-tau/Aβ42 performed the best. Conclusions: Our results independently confirm the analytical and clinical performance of the MSD CSF t-tau and Aβ42 assays. Based on a large, multi-center, clinically-diagnosed cohort, we propose for the first time candidate diagnostic cut-offs for MSD measured CSF t-tau, Aβ42, and t-tau/Aβ42. However, these values needs to be refined as more subjects are included and the assays are tested by other laboratories.",
keywords = "Alzheimer's disease, Aβ, cerebrospinal fluid, Meso Scale Discovery, tau",
author = "Catherine Pan and An{\'e} Korff and Douglas Galasko and Carmen Ginghina and Elaine Peskind and Ge Li and Joseph Quinn and Montine, {Thomas J.} and Kevin Cain and Min Shi and Jing Zhang",
year = "2015",
doi = "10.3233/JAD-143099",
language = "English (US)",
volume = "45",
pages = "709--719",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease

AU - Pan, Catherine

AU - Korff, Ané

AU - Galasko, Douglas

AU - Ginghina, Carmen

AU - Peskind, Elaine

AU - Li, Ge

AU - Quinn, Joseph

AU - Montine, Thomas J.

AU - Cain, Kevin

AU - Shi, Min

AU - Zhang, Jing

PY - 2015

Y1 - 2015

N2 - Background: Meso Scale Discovery (MSD) recently established electrochemiluminescence-based assays to measure cerebrospinal fluid (CSF) levels of total tau (t-tau) and amyloid-β 1-42 peptide (Aβ42) that can aid in the diagnosis of Alzheimer's disease (AD). The goal of this investigation is to independently evaluate this platform and establish cut-off values of these biomarkers for AD diagnosis. Objective: To validate the analytical and clinical performance of the MSD t-tau and Aβ42 kits and propose diagnostic cut-off values for the field. Methods: The analytical performance of the CSF t-tau and Aβ42 assays was determined, followed by assessment of diagnostic performance of CSF t-tau, Aβ42, and t-tau/Aβ42 in three clinically characterized cohorts. Results: Both MSD assays demonstrated consistent and stable analytical performance, as well as resistance to several important pre-analytic variables. Diagnostically, t-tau/Aβ42 performed the best. Conclusions: Our results independently confirm the analytical and clinical performance of the MSD CSF t-tau and Aβ42 assays. Based on a large, multi-center, clinically-diagnosed cohort, we propose for the first time candidate diagnostic cut-offs for MSD measured CSF t-tau, Aβ42, and t-tau/Aβ42. However, these values needs to be refined as more subjects are included and the assays are tested by other laboratories.

AB - Background: Meso Scale Discovery (MSD) recently established electrochemiluminescence-based assays to measure cerebrospinal fluid (CSF) levels of total tau (t-tau) and amyloid-β 1-42 peptide (Aβ42) that can aid in the diagnosis of Alzheimer's disease (AD). The goal of this investigation is to independently evaluate this platform and establish cut-off values of these biomarkers for AD diagnosis. Objective: To validate the analytical and clinical performance of the MSD t-tau and Aβ42 kits and propose diagnostic cut-off values for the field. Methods: The analytical performance of the CSF t-tau and Aβ42 assays was determined, followed by assessment of diagnostic performance of CSF t-tau, Aβ42, and t-tau/Aβ42 in three clinically characterized cohorts. Results: Both MSD assays demonstrated consistent and stable analytical performance, as well as resistance to several important pre-analytic variables. Diagnostically, t-tau/Aβ42 performed the best. Conclusions: Our results independently confirm the analytical and clinical performance of the MSD CSF t-tau and Aβ42 assays. Based on a large, multi-center, clinically-diagnosed cohort, we propose for the first time candidate diagnostic cut-offs for MSD measured CSF t-tau, Aβ42, and t-tau/Aβ42. However, these values needs to be refined as more subjects are included and the assays are tested by other laboratories.

KW - Alzheimer's disease

KW - Aβ

KW - cerebrospinal fluid

KW - Meso Scale Discovery

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=84925798585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925798585&partnerID=8YFLogxK

U2 - 10.3233/JAD-143099

DO - 10.3233/JAD-143099

M3 - Article

VL - 45

SP - 709

EP - 719

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -